Invalid Symbol

Stock Research for AMBI

AMBI
Current Price

$


Latest Update:

High
$
Low
$
Close
$
Volume
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

AMBI Stock Chart & Research Data

The AMBI chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the AMBI chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


AMBI Due diligence Resources & Stock Charts

The AMBI stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View AMBI Detailed Price Forecast - CNN Money CNN View AMBI Detailed Summary - Google Finance
Yahoo View AMBI Detailed Summary - Yahoo! Finance Zacks View AMBI Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View AMBI Trends & Analysis - Trade-Ideas Barrons View AMBI Major Holders - Barrons
NASDAQ View AMBI Call Transcripts - NASDAQ Seeking View AMBI Breaking News & Analysis - Seeking Alpha
Spotlight View AMBI Annual Report - CompanySpotlight.com OTC Report View AMBI OTC Short Report - OTCShortReport.com
TradeKing View AMBI Fundamentals - TradeKing Charts View AMBI SEC Filings - Bar Chart
WSJ View Historical Prices for AMBI - The WSJ Morningstar View Performance/Total Return for AMBI - Morningstar
MarketWatch View the Analyst Estimates for AMBI - MarketWatch CNBC View the Earnings History for AMBI - CNBC
StockMarketWatch View the AMBI Earnings - StockMarketWatch MacroAxis View AMBI Buy or Sell Recommendations - MacroAxis
Bullish View the AMBI Bullish Patterns - American Bulls Short Pains View AMBI Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View AMBI Stock Mentions - StockTwits PennyStocks View AMBI Stock Mentions - PennyStockTweets
Twitter View AMBI Stock Mentions - Twitter Invest Hub View AMBI Investment Forum News - Investor Hub
Yahoo View AMBI Stock Mentions - Yahoo! Message Board Seeking Alpha View AMBI Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for AMBI - SECform4.com Insider Cow View Insider Transactions for AMBI - Insider Cow
CNBC View AMBI Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for AMBI - OTC Markets
Yahoo View Insider Transactions for AMBI - Yahoo! Finance NASDAQ View Institutional Holdings for AMBI - NASDAQ


Stock Charts

FinViz View AMBI Stock Insight & Charts - FinViz.com StockCharts View AMBI Investment Charts - StockCharts.com
BarChart View AMBI Stock Overview & Charts - BarChart Trading View View AMBI User Generated Charts - Trading View


Latest Financial News for AMBI

AmbiCom Holdings Inc. ( OTC PINK: AMBI ) Announces New Management, Line of Credit, and the Filing of Lawsuit Against PC Drivers Headquarters L.P.
Posted on Wednesday February 01, 2017

SAN JOSE, CA / ACCESSWIRE / February 1, 2017 / AmbiCom Holdings ( OTC PINK: AMBI ) announced today that new management is being brought in to restructure the company. A new CEO, Alain Lewand, has been ...



Posted on Wednesday December 31, 1969



Posted on Wednesday December 31, 1969



Posted on Wednesday December 31, 1969


Buy The Fear With Ambit Biosciences
Seeking Alpha - Dec 5, 2013
Ambit Biosciences (NASDAQ:AMBI) lost over 33% of its market cap, as of market close on December 4th, when the company reported it is not planning to file a new drug application (NDA) for accelerated approval of quizartinib.

Japan's Daiichi Sankyo to acquire US biopharma Ambit Biosciences
Reuters UK - Sep 28, 2014
TOKYO (Reuters) - Japanese drugmaker Daiichi Sankyo Co Ltd (4568.T) has agreed to acquire U.S. biopharmaceutical company Ambit Biosciences Corp AMBI.O in a deal valued up to $410 million as it looks to build its presence in oncology, the companies said ...
Is Ambit Biosciences Getting Enough in Its Buyout? - 24/7 Wall St.
Daiichi Sankyo Offers $315M Up Front to Get Ambit and Leukemia Drug - Xconomy

Reviewing Ambit Biosciences (AMBI) & Anika Therapeutics (ANIK)
StockNewsTimes - 13 hours ago
Ambit Biosciences logo Ambit Biosciences Corporation is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by ...

As Ambit Eyes IPO, Astellas Drops FLT3 Partnership
BioWorld Online - Mar 12, 2013
Astellas Pharma Inc. dropped the hammer on Ambit Biosciences Corp., ending its collaboration on the joint development and commercialization of FMS-like tyrosine kinase-3 (FLT3) inhibitors, including lead program quizartinib (formerly AC220), effective ...

Enter a stock symbol to view the stock details.